Table 1.
Descriptive characteristics of patients treated with intravenous vs. intraperitoneal chemotherapy for stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease between 1995 and 2012 (n = 1263)
| Initial cohort (n = 1263) | Propensity score-matched cohort (n = 548) | |||||
|---|---|---|---|---|---|---|
| intravenous | intraperitoneal | SDM | intravenous | intraperitoneal | SDMa | |
| n = 847 | n = 416 | n = 381 | n = 381 | |||
| Characteristics | (71.4 %) | (28.6 %) | (50 %) | (50 %) | ||
| Age (y, mean) | 54.3 | 52.6 | 0.017 | 52.7 | 52.6 | 0.002 |
| Stage (%) | ||||||
| III | 671 (90.1 %) | 267 (89.6 %) | 0.014 | 254 (92.7 %) | 252 (92.0 %) | 0.013 |
| IV | 74 (9.9 %) | 31 (10.4 %) | −0.020 | 20 (7.3 %) | 22 (8.0 %) | −0.021 |
| Grade (%) | ||||||
| 1 | 119 (16.0 %) | 43 (14.4 %) | 0.011 | 33 (12.0 %) | 37 (13.5 %) | −0.021 |
| 2 | 429 (57.6 %) | 180 (60.4 %) | −0.008 | 178 (65.0 %) | 176 (64.2 %) | 0.017 |
| 3 | 197 (26.4 %) | 75 (25.2 %) | 0.009 | 63 (23.0 %) | 61 (22.2 %) | 0.011 |
| Histologic subtype (%) | ||||||
| Serous | 371 (49.8 %) | 145 (48.7 %) | 0.016 | 142 (51.8 %) | 140 (51.1 %) | 0.006 |
| Mucinous | 75 (10.1 %) | 26 (8.7 %) | 0.014 | 21 (7.7 %) | 24 (8.8 %) | −0.016 |
| Clear cell | 109 (14.6 %) | 41 (13.8 %) | 0.007 | 41 (15.0 %) | 38 (13.9 %) | 0.014 |
| Endometrioid | 83 (11.1 %) | 45 (15.1 %) | −0.037 | 48 (17.5 %) | 45 (16.4 %) | 0.010 |
| Mixed or othersa | 107 (14.4 %) | 41 (13.8 %) | 0.009 | 22 (8.0 %) | 27 (9.9 %) | −0.019 |
| Front-line regimen (%) | ||||||
| Paclitaxel based | 661 (88.8 %) | 259 (81.2 %) | 0.074 | 245 (89.4 %) | 248 (90.5 %) | −0.008 |
| Not paclitaxel based | 84 (11.3 %) | 39 (13.1 %) | −0.017 | 29 (10.6 %) | 26 (9.5 %) | 0.009 |
| Consolidation chemotherapy (%) | ||||||
| No | 622 (83.5 %) | 242 (83.9 %) | −0.007 | 202 (73.7 %) | 203 (74.1 %) | −0.005 |
| Yes | 123 (16.5 %) | 56 (16.1 %) | 0.008 | 72 (26.3 %) | 71 (25.9 %) | 0.006 |
| GOG performance status | ||||||
| ≤ 1 | 649 (87.1 %) | 250 (83.9 %) | 0.026 | 241 (88.0 %) | 239 (87.2 %) | 0.003 |
| ≥ 2 | 96 (12.9 %) | 48 (16.1 %) | −0.027 | 33 (12.0 %) | 35 (12.8 %) | −0.006 |
| Charlson comorbidity index (%) | ||||||
| 0 | 637 (85.5 %) | 231 (77.5 %) | 0.103 | 223 (81.4 %) | 219 (80.0 %) | 0.008 |
| ≥ 1 | 108 (14.5 %) | 67 (22.5 %) | −0.146 | 51 (18.6 %) | 55 (20.0 %) | −0.014 |
Abbreviations SDM standardized difference of means
aOthers histology include: undifferentiated and unclassified epithelial carcinoma